short term potential

I was a little surprised that this did not move up last week. With the Artimist trials nearing completion and possibly finished within a month this stock is in a much better position than 12 months ago when we all thought the trials would never be completed due to problems with PP.
They have clearly sorted out the trials and completion will mark a major milestone for ems.
My biggest surprise was the 2 trial updates within a month. Clearly things are now moving well in that respect.
The trial results will not take long after completion of the trial, as the results of reatment are known shortly after the patient has been treated.
I think the whole community expects a positive trial result as the efficacy of artimist in malarial patients with complications is well documented.